| Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) (NCT05415410) | VectivBio AG | 2022-05-25 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) (NCT05263999) | Equillium | 2022-04-29 |
| Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD (NCT05094765) | Shenzhen Xbiome Biotech Co., Ltd. | 2021-11-01 |
| Outcomes of Patients After Allo-HSCT With Decitabine and NAC (NCT04945096) | The First Affiliated Hospital of Soochow University | 2021-07-01 |
| Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (NCT07508345) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2021-06-04 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease (NCT06938165) | Nanfang Hospital, Southern Medical University | 2020-04-27 |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation (NCT03680092) | Dimitrios Tzachanis, MD PhD | 2019-11-26 |
| Allogeneic Skin Grafting (NCT04015947) | University of Minnesota | 2019-08-01 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (NCT03763318) | Biocon Limited | 2019-07-15 |
| High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT03945591) | NYU Langone Health | 2019-06-20 |
| Itacitinib for Low Risk GVHD (NCT03846479) | John Levine | 2019-03-25 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (NCT03605927) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-15 |
| A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD (NCT03459040) | John Levine | 2018-08-17 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-08 |
| CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT (NCT02942173) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2016-10-01 |
| Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients (NCT02712762) | Singapore National Eye Centre | 2016-06-01 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention (NCT02588339) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-04 |
| Comparison of Two Automated Mononuclear Collection Systems in Patients Undergoing Extracorporeal Photochemotherapy. A Cross-over Equivalence Study. (MNC_CMNC) (NCT02490163) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2015-08-01 |
| Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation (NCT02338232) | Hackensack Meridian Health | 2015-07-07 |
| Immuno-regulatory Profiling of T Cells in GVHD Treated With Extracorporeal Photopheresis (NCT03851601) | Henry Ford Health System | 2014-08-26 |
| Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation (NCT03233659) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2014-08-12 |
| Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients (NCT02156479) | Lophius Biosciences GmbH | 2014-07-01 |
| 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 (NCT02441075) | Nationwide Children's Hospital | 2014-05-01 |
| IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD (NCT02066051) | Mayo Clinic | 2013-10-01 |
| Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (NCT01295710) | Neovii Biotech | 2011-10-10 |
| Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation (NCT00282282) | Dana-Farber Cancer Institute | 2006-01-01 |